Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Video

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy

World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy

CGTLive Staff
November 21st 2024
Article

In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.

Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024

Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024

Noah Stansfield
November 20th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – November 15, 2024

CGTLive Staff
November 15th 2024
Article

Review top news and interview highlights from the week ending November 15, 2024.

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths

Noah Stansfield
November 15th 2024
Article

The safety data set for the trial included 39 patients who were treated with ALLO-316.

Around the Helix: Cell and Gene Therapy Company Updates – November 13, 2024

Around the Helix: Cell and Gene Therapy Company Updates – November 13, 2024

Noah Stansfield
November 13th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Gastric Cancer Awareness Month 2024: Looking Back at Progress for Cell Therapy

Gastric Cancer Awareness Month 2024: Looking Back at Progress for Cell Therapy

CGTLive Staff
November 11th 2024
Article

In observance of Gastric Cancer Awareness Month, held annually in November, we took a look back at the past few months' news in cell therapy for gastric cancer indications.

© 2024 MJH Life Sciences

All rights reserved.